Articles tagged with Lung Cancer
Researchers developed a deep learning model that accurately predicts lung cancer patients' survival expectancy, significantly better than traditional machine learning models. The model can analyze large amounts of data to understand how various factors affect lung cancer survival periods.
The NEOSTAR trial found that combination therapy produced significant clinical benefits, including higher major pathologic response rates and enhanced tumor immune cell infiltration. The treatment also triggered immunological memory, which may translate to a reduced risk of tumor relapse.
A new algorithm developed by researchers at the University of Copenhagen can detect unusual disease trajectories in COPD patients that may indicate a different diagnosis, such as lung cancer. The algorithm was trained on data from 284,000 patients and identified approximately 69,000 typical disease trajectories.
A study published in Oncotarget found that hemoglobin-based oxygen carriers increase chemotherapy effectiveness in non-small cell lung cancer. PolyHb administration attenuates tumor growth without alleviating hypoxia, suggesting a potential strategy to enhance cisplatin sensitivity.
Patients with non-small cell lung cancer who enrolled in a phase III early-stage trial showed a high rate of smoking reduction and cessation following study entry. Smoking rates were significantly lower among never-smokers, leading to improved overall survival compared to smokers.
Lung cancer is a leading cause of death in Singapore and the world, with Asian populations exhibiting distinct genetic alterations. The World Conference on Lung Cancer Singapore presented new data on EGFR mutation and TKI-drug resistance, highlighting the need for targeted treatment approaches.
The phase III CROWN study showed that lorlatinib significantly improved progression-free survival compared to crizotinib in patients with previously untreated advanced ALK-positive NSCLC. Patient-reported outcomes also indicated comparable time to treatment deterioration for lung cancer symptoms between the two treatments.
A host immune classifier test may help guide immunotherapy treatment decisions for patients with newly diagnosed non-small cell lung cancer. The test, which measures inflammation in the body, is associated with longer overall survival and better treatment response.
The Checkpoint Blockade for Inhibition of Relapsed Mesothelioma (CONFIRM) study demonstrated that nivolumab significantly improves overall and progression-free survival in patients with relapsed malignant mesothelioma. The treatment also showed a consistent safety profile without new adverse effects.
Researchers analyzed mRNA expression levels of molecular markers ERCC1 and thymidylate synthase in patients with resected stage II-III non-small cell lung cancer. The study found no correlation between these markers and overall survival, contradicting previous hopes for a personalized chemotherapy approach.
The LCMC3 study showed that neoadjuvant atezolizumab was well tolerated and met its primary endpoint, achieving a major pathologic response rate of 21% in patients without EGFR/ALK mutations. The therapy also showed high complete resection rates and low perioperative morbidity and mortality.
A nationwide lung cancer LDCT screening study found the effectiveness of low-dose computed tomography (LDCT) screening in a pre-defined, never-smoker population. The study revealed that family history significantly increased lung cancer risk, and most participants had stage 0 or 1 disease.
Research found that black patients diagnosed with non-small cell lung cancer are more likely to be diagnosed at an advanced stage and have lower chances of receiving surgery. Additionally, they experience significantly reduced cancer-specific survival rates compared to their white counterparts.
Two ADAURA analyses presented at the International Association for the Study of Lung Cancer's 2020 World Conference on Lung Cancer (WCLC) Singapore support the use of Osimertinib as a new treatment strategy for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer. The data show significant disease-free surviva...
Researchers presented two radiation oncology trials that aimed to improve local tumor control in NSCLC patients. One trial found no significant difference in 2-year local-regional tumor progression-free rates between adaptive and standard radiation therapy arms, while another study demonstrated excellent local control rates with dose e...
Researchers investigating lung cancer treatment during the pandemic found that patients with lung cancer experience higher levels of psychological distress and anxiety about accessing care. The study also revealed that patient advocacy organizations face challenges in providing support due to decreased funding.
Researchers found that combining ipilimumab with pembrolizumab did not significantly improve overall survival or progression-free survival for patients with NSCLC. The combination was also associated with greater treatment-related adverse events.
The NRG Oncology trial shows improved in-field tumor control with adaptive radiotherapy, increasing local-regional tumor control by 11% and primary tumor control by 17%. The study's results suggest individualizing radiotherapy dose prescriptions according to patient's intrinsic sensitivity for better survival outcomes.
In the phase II CodeBreak 100 trial, sotorasib demonstrated a confirmed response rate of 32.2%, a median duration of response of 10.9 months, and a median progression-free survival of 6.3 months in patients with pretreated NSCLC and KRAS p.G12C mutations.
Research highlights barriers to lung cancer care for marginalized communities, including racial and ethnic minorities, LGBTQ+ individuals, and low-income patients. Key findings also show sex disparities in lung cancer incidence rates across countries.
Researchers have developed a new method, Cell Heterogeneity-Adjusted cLonal Methylation (CHALM), that improves the prediction of gene expression from DNA methylation data. This method has been shown to identify more reliable biomarkers for cancer diagnosis, potentially leading to better early detection.
Researchers at McMaster University have developed a novel combination of two immunotherapies that induces robust tumour destruction against lung cancer. The new treatment uses one form of therapy to kill cancer cells and triggers changes that enable the second therapy to finish the job.
A study in Journal of Thoracic Oncology found that routine thoracic surgery and invasive examinations were performed safely during the COVID-19 pandemic. The study analyzed data from a single Chinese hospital and showed that careful screening, patient protection, and effective medical staff precautions enabled safe operations.
A recent study reported a significant drop in low-dose computed tomography (LDCT) screening for lung cancer during the COVID-19 pandemic. Despite resuming full operations, new patient monthly LDCT rates remained low, and patients were more likely to miss appointments, increasing the no-show rate from 15% to 40%. This led to a rise in m...
Researchers at Temple University Health System aim to break down race-related barriers to lung cancer screening and care among Blacks and African Americans. The two-year grant will support the expansion of a successful lung cancer screening program using a multi-specialty, integrated model.
A recent study by University of Cincinnati Cancer Center researchers shows that the pandemic had a negative impact on both preventive screening and patient outcomes for lung cancer. The team found that total monthly CT scans and new patient scans significantly decreased during the COVID-19 period, leading to increased proportion of sus...
Scientists have developed a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. The treatment has shown promise in treating aggressive subtypes of cancers with specific mutations in genes called RAS or NF1.
A study has found that certain types of mouth bacteria are associated with an increased risk of lung cancer in non-smokers. The findings suggest that a wider range of bacterial species is linked to a lower risk, while specific types like Firmicutes and Spirochaetes may contribute to heightened risk.
The new guidelines provide uniform standards for treating brain tumour complications such as epileptic attacks, brain edema, haemorrhage, or thrombosis worldwide. The initiative aims to increase patient safety and improve treatment outcomes.
Research suggests stress hormones and immune cells may contribute to tumor recurrence by reactivating dormant cancer cells. Targeting stress hormones with approved drugs like beta-blockers could potentially prevent tumors from returning.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new target for aggressive lung adenocarcinomas driven by the KEAP1 and STK11 mutations. By inhibiting ferroptosis, these tumors rely on this blockade to grow and survive.
A new study has shed light on the role of p53 target gene Zmat3 in lymphoma and lung cancer development. Researchers found that disabling Zmat3 had little impact on tumor development, suggesting that other proteins may be involved in preventing cancer formation.
A study led by Massachusetts General Hospital found that early treatment with lorlatinib improved survival rates and reduced the risk of brain metastasis in ALK-positive lung cancer patients. Lorlatinib was shown to be effective as a first-line therapy, reducing the risk of cancer progression or death by 72%.
A study by University of Utah researchers found that experienced radiologists can miss clear abnormalities when looking for one specific issue, highlighting the limits of human cognition. The experiment demonstrates that years of experience don't guarantee detection of critical findings.
Researchers found an overall 17% risk reduction for metastatic or fatal cancer and a 38% reduction among those with normal BMI. The study suggests that vitamin D may reduce the risk of developing advanced cancers, particularly in individuals with normal weight.
Researchers found patients with a particular type of human leukocyte antigen (HLA) B44 were more likely to benefit from immunotherapy in melanoma but not non-small cell lung cancer. The study identified mutations driving the different responses, paving the way for better patient stratification and potential therapy design.
A new model predicts the risk of severe side effects in cancer patients during chemotherapy by analyzing genetic signatures. The study identified a network of genes linked to bone marrow toxicity and developed a classification system to predict patient risk.
Researchers from MD Anderson Cancer Center present promising clinical data on combination therapies for patients with metastatic melanoma and advanced refractory solid tumors. The treatments showed activity in activating immune pathways, leading to antitumor responses.
A study published in Cancer Discovery found that patients with advanced-stage lung cancer had greater enrichment of oral commensals in the lung than those with early-stage disease, leading to decreased survival. The presence of specific bacteria was associated with tumor progression and activation of inflammatory pathways.
A meta-analysis of eight randomized clinical trials found that low-dose CT screening reduces lung cancer-caused death by 0.4%, translating to one preventable death per 250 at-risk adults. The study suggests the benefits may outweigh potential harms from overdiagnosis, aligning with US Preventive Services Task Force recommendations.
Researchers found a significant increase in cancer survival rates among Medicaid expansion states compared to non-expansion states. The study analyzed data from breast, colorectal, and lung cancer patients and discovered improved survival outcomes following the expansion of healthcare coverage.
A new report from UCSF links climate change to a significant increase in global cancer rates, particularly lung, skin, and gastrointestinal cancers. The study highlights the need for urgent action to mitigate climate change and reduce air pollution to prevent cancer cases and deaths.
A large-scale study found that LDCT scans can identify a significant number of adults with low bone mineral density, equating to 49 million and 22.8 million Chinese citizens, respectively. The study revealed an unexpectedly high prevalence of osteoporosis in men, which may impact management strategies.
Dr. Donna D. Zhang's research focuses on harnessing nuclear factor erythroid-2-related factor 2 to prevent or treat arsenic-induced diseases. She aims to identify new pharmaceuticals to address adverse health effects resulting from arsenic exposure.
A new study examined recent data on African American patients with early-stage non-small cell lung cancer and found that while Black patients are now more likely to receive effective treatments, disparities persist. The use of surgery remained a significant disparity across racial groups, despite increasing utilization over time.
A new study from Penn Medicine found that proton therapy reduces the risk of radiation-induced heart diseases in lung cancer patients. Mini-strokes and heart attacks were significantly less common among patients who underwent proton therapy compared to those treated with conventional photon-based radiation therapy.
Researchers developed a vaccine targeting KRAS gene mutations in lung, bowel and pancreatic cancers. In mice studies, vaccinated animals showed improved survival rates compared to unvaccinated ones.
A new deep learning model using PET/CT imaging can classify EGFR mutation status in non-small cell lung cancer, predicting the most effective treatment option. The model shows promise as a clinical decision support tool for personalized treatment choices.
The study reveals that efavirenz alters the gene expression of important factors essential for genomic stability, particularly down-regulating S-phase and DNA replication genes. This suggests that efavirenz may be used in synergy with chemo/radiotherapy to treat lung cancer.
The HAMRC will investigate novel approaches to characterize lung cancer epidemiology, somatic mutation burden, and the relationship between HIV-1 infection and accelerated aging. The team aims to develop diagnostic computational imaging algorithms to discern lung cancer from respiratory infections.
A pilot study comparing liquid biopsy with tissue-based test found that liquid biopsy results were approximately 10 days faster than tissue biopsy. Liquid biopsy identified actionable genes in 14 cases, while tissue biopsy only detected them in 11 cases.
Researchers at Princess Margaret Cancer Centre found that over 80% of advanced NSCLC patients had genomic alterations detected in cfDNA. Liquid biopsies were shown to be a timely and effective method for diagnosing and monitoring the disease, with actionable alterations detected in over 56% of treatment-naïve patients.
A study suggests that a national biennial lung cancer screening program could be cost-effective for Māori in New Zealand. The program aims to reduce population inequities relating to lung cancer among Māori. Early-stage lung cancer can be curable, and screening may help save lives by identifying the disease at an early stage.
A clinical trial of selpercatinib has shown promising results for patients with non-small cell lung cancer, achieving high response rates and prolonged survival. The drug specifically targets cancers driven by mutations in the gene RET, with minimal side effects.
A phase 1 clinical trial of sotorasib (AMG 510) demonstrated anti-cancer activity in patients with heavily pretreated advanced solid tumors. Patients with non-small cell lung cancer had a 32% response rate and median progression-free survival of 6.3 months.
In a Phase I clinical trial, sotorasib achieved a confirmed response rate of 32.2% and disease control rate of 88.1% in patients with KRAS G12C-mutant non-small cell lung cancer, with durable clinical benefits and manageable toxicities
A large randomized trial found that post-operative radiotherapy (PORT) does not significantly improve disease-free survival in completely resected non-small-cell lung cancer (NSCLC) patients. The study included 501 patients and showed no significant difference in overall survival between the PORT group and the control group.
A recent study found that combining aspirin, metformin, and statins may decrease lung cancer incidence and mortality. The research analyzed data from over 732,000 Koreans and discovered that concurrent use of these medications was associated with lower risk and mortality rates.
A recent Finnish twin study reveals that smoking is the primary cause of subarachnoid hemorrhages, which account for up to half of all deaths within months of the haemorrhage. The research indicates a strong causal link between smoking and fatal brain haemorrhages, highlighting the importance of quitting or never starting smoking.
Researchers have developed an accelerated platform to identify and test potential treatments for early-stage lung cancer using 'organoids' created from lung cells. The studies revealed reduced expression of genes that are markers of mature lung alveolar cells, and increased expression of genes involved in early lung development.